Terms: = Prostate cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
447 results:
1. Challenges in Diagnosis and treatment of Male Hypogonadism.
Purnamasari D
Acta Med Indones; 2024 Jan; 56(1):1-2. PubMed ID: 38561883
[TBL] [Abstract] [Full Text] [Related]
2. Very high-energy electron therapy as light-particle alternative to transmission proton FLASH therapy - An evaluation of dosimetric performances.
Böhlen TT; Germond JF; Desorgher L; Veres I; Bratel A; Landström E; Engwall E; Herrera FG; Ozsahin EM; Bourhis J; Bochud F; Moeckli R
Radiother Oncol; 2024 May; 194():110177. PubMed ID: 38378075
[TBL] [Abstract] [Full Text] [Related]
3. Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiation.
Sanguineti G; Pavarini M; Munoz F; Magli A; Cante D; Garibaldi E; Gebbia A; Noris Chiorda B; Girelli G; Villa E; Faiella A; Magdalena Waskiewicz J; Avuzzi B; Pastorino A; Moretti E; Rago L; Statuto T; Gatti M; Rancati T; Valdagni R; Luigi Vavassori V; Gisella Di Muzio N; Fiorino C; Cozzarini C
Radiother Oncol; 2024 Mar; 192():110088. PubMed ID: 38199284
[TBL] [Abstract] [Full Text] [Related]
4. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
[TBL] [Abstract] [Full Text] [Related]
5. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
[TBL] [Abstract] [Full Text] [Related]
6. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
[TBL] [Abstract] [Full Text] [Related]
7. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Shen J; Chowdhury S; Agarwal N; Karsh LI; Oudard S; Gartrell BA; Feyerabend S; Saad F; Pieczonka CM; Chi KN; Brookman-May SD; Rooney B; Bhaumik A; McCarthy SA; Bevans KB; Mundle SD; Small EJ; Smith MR; Graff JN
Br J Cancer; 2024 Jan; 130(1):73-81. PubMed ID: 37951974
[TBL] [Abstract] [Full Text] [Related]
8. cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in cancer Burden, 2020-2050: A Statistical Modeling Study.
Nguyen PT; Hori M; Matsuda T; Katanoda K
Cancer Epidemiol Biomarkers Prev; 2023 Dec; 32(12):1756-1770. PubMed ID: 37756571
[TBL] [Abstract] [Full Text] [Related]
9. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
[TBL] [Abstract] [Full Text] [Related]
10. The Balance Between the Therapeutic Efficacy and Safety of [
Verhoeven M; Haeck J; de Blois E; Orlandi F; Barbato D; Tedesco M; Konijnenberg M; Dalm SU
Mol Imaging Biol; 2024 Feb; 26(1):114-123. PubMed ID: 37640941
[TBL] [Abstract] [Full Text] [Related]
11. Predictors of Financial Toxicity Among United States prostate cancer Survivors: Results From a National Survey.
Stone BV; Labban M; Filipas DK; Beatrici E; Frego N; Qian ZJ; Voleti SS; Lipsitz SR; Kibel AS; Trinh QD; Cole AP
Urol Pract; 2023 Sep; 10(5):459-466. PubMed ID: 37498685
[TBL] [Abstract] [Full Text] [Related]
12. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH
Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291
[TBL] [Abstract] [Full Text] [Related]
13. A rare case of prostate cancer initially presented by disseminated intravascular coagulation-related subdural hemorrhage.
Shafie M; Shahmohamadi E; Hadizadeh A; Hasanzadeh A; Gholampour G; Parsa S
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1868. PubMed ID: 37435692
[TBL] [Abstract] [Full Text] [Related]
14. Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification.
Yang X; Tan YG; Gatsinga R; Chen W; Huang HH; Loong JTK; Chua MLK; Rajasekaran T; Kanesvaran R; Tay KJ; Chen K; Yuen JSP
Int J Urol; 2023 Nov; 30(11):991-999. PubMed ID: 37431969
[TBL] [Abstract] [Full Text] [Related]
15. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant prostate cancer.
Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H
Clin Cancer Res; 2023 Sep; 29(17):3292-3300. PubMed ID: 37339186
[TBL] [Abstract] [Full Text] [Related]
16. Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant prostate cancer Patients Undergoing prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
Hartrampf PE; Mihatsch PW; Seitz AK; Solnes LB; Rowe SP; Pomper MG; Kübler H; Bley TA; Buck AK; Werner RA
J Nucl Med; 2023 Aug; 64(8):1272-1278. PubMed ID: 37290794
[TBL] [Abstract] [Full Text] [Related]
17. Health-related quality of life and pain outcomes with [
Fizazi K; Herrmann K; Krause BJ; Rahbar K; Chi KN; Morris MJ; Sartor O; Tagawa ST; Kendi AT; Vogelzang N; Calais J; Nagarajah J; Wei XX; Koshkin VS; Beauregard JM; Chang B; Ghouse R; DeSilvio M; Messmann RA; de Bono J
Lancet Oncol; 2023 Jun; 24(6):597-610. PubMed ID: 37269841
[TBL] [Abstract] [Full Text] [Related]
18. Moderators of resistance-based exercise programs' effect on sarcopenia-related measures in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis.
Lopez P; Newton RU; Taaffe DR; Winters-Stone K; Galvão DA; Buffart LM
J Geriatr Oncol; 2023 Jun; 14(5):101535. PubMed ID: 37229882
[TBL] [Abstract] [Full Text] [Related]
19. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive prostate cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
[TBL] [Abstract] [Full Text] [Related]
20. Improving delivery efficiency using spots and energy layers reduction algorithms based on a large momentum acceptance beamline.
Wang W; Liu X; Yang Z; Liao Y; Li P; Zhao R; Qin B
Med Phys; 2023 Aug; 50(8):5189-5200. PubMed ID: 37099491
[TBL] [Abstract] [Full Text] [Related]
[Next]
